Explore
Companies
Investors
Top 50
Streams
Trending tech news
Latest investments
Latest acquisitions
Products
Automate
Trackers
Innovation Services
About Index
Index
By TNW
Log in
Register
Forbion Capital Partners
1202
Forbion Capital Partners
Forbion Capital Partners invests in Life Sciences and Biomedical Technology companies developing worldclass drugs and technologies, with a clear focus on product development..
Suggest edits
Type
B2b
Founded
2007
Follow us
Companies in the same industry
Albion Capital
Charlesbank Capital Partners
Five Arrows Principal Investments
Beyond Ventures
Trive Capital
Kinara Capital
Generate Capital
Robo Global Robotics & Automation
Olympus Partners
Aeris Partners
Overview
News
Investments
24
Portfolio
Portfolio Tracker
Add info
$450,000,000
FinSMEs
Bayer to Buy KaNDy Therapeutics
$115,000,000
Venture capital
FinSMEs
Dyne Therapeutics Raises $115M in Equity Financing
$62,500,000
Venture capital (Series A)
FinSMEs
Prilenia Therapeutics Raises $62.5M in Series A Funding
€25,000,000
Venture capital (Series A)
FinSMEs
Azafaros Closes €25M Series A Financing
$40,000,000
Venture capital (Series B)
FinSMEs
NorthSea Therapeutics Raises US $40M in Series B Financing
PE HUB
Hookipa Pharma debuts IPO
$37,400,000
Venture capital (Series D)
FinSMEs
Hookipa Pharma Raises $37.4M in Series D Financing
MedCity News
bluebird bio's stock tanks after report of serious toxicity in sickle cell patient
$80,000,000
Venture capital
FinSMEs
Milestone Pharmaceuticals Raises $80M in Equity Funding
Funding
Health
£25,000,000
Venture capital (Series C)
FinSMEs
,
MedCity News
,
PE HUB
KaNDy Therapeutics Raises £25M in Series C Financing
Health
Funding
FinSMEs
Lundbeck to Acquire Prexton Therapeutics, for €905M
Health
Science
$59,600,000
Venture capital (Series C)
PE HUB
| Hookipa Biotech scores $59.6 mln Series C
PE HUB
Merck to buy VC-backed Rigontec
Health
Funding
$30,000,000
Venture capital (Series C)
citybizlist
citybizlist : Exosome Diagnostics Raises $30M Series C
€17,500,000
Post-IPO equity
morningstar
,
Labiotech.eu
Cellnovo Successfully Raises €17.5 Million from Healthcare Investors
$250,000,000
Post-IPO equity
Twitter
Boston Business on Twitter
$18,400,000
Venture capital (Series A)
stevenagecatalyst
,
biospace
Stevenage BioScience Catalyst | The Stevenage Voice - February 2013 |
£23,000,000
Venture capital (Series B)
PE Hub
,
GEN
,
pharmatimes
NeRRE Therapeutics picks up Series B funds
€5,400,000
Venture capital
cellnovo
Press Releases | The Cellnovo Diabetes Management System
Stock markets
rigontec
Rigontec GmbH – A Dual Approach To Treat Cancer is a privately held biopharmaceutical company that develops RNA-based im...
Health
Science
Funding
